Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Erdafitinib Tablet vs Capsule
NCT02231489Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of erdafitinib in urothelial carcinoma (UC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Absolute Bioavailability and Relative Bioavailability. Started Sep 2014; status: completed.
02
Drugs
erdafitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02231489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231489.